OBN are holding their next BioTuesday event on 2 July, in collaboration with Oxford Cancer, the BioEscalator and the University of Oxford’s Business Partnerships Office, where they will be spotlighting:

‘Oncology Precision Prevention Treatments and

the Expected Impact on People with High-Risk Conditions’

Research and clinical trials in cancer prevention are critical for improving patient outcomes and reducing pressure on healthcare systems. This new field of precision prevention exploits biological insights into risk factors and cancer development to precisely target interventions to individuals at high risk, with the aim of delaying or preventing cancer.

Oxford University hosts the UK’s first and only Cancer Research UK-accredited trials centre specialising in cancer precision prevention studies and is changing the way that these trials are run. Compared to traditional cancer prevention trials, precision prevention trials are more focused, smaller and shorter, and thus more attractive to commercial timelines.

Expert speakers at this event will highlight the innovations in cancer prevention trials and explore the impact on pharma and people affected by a high-risk condition.

Outline Programme:

17:00 – 17:30 – Registration & networking

17:30 – 19:00 – Presentations & discussion:

Introductory keynote from Sarah Blagden, Professor of Experimental Oncology, University of Oxford 

Followed by a Chaired discussion with:

• Anna Fry, PPI representative
• Kirsty Wydenbach, Head of Regulatory Strategy at Weatherden 
• Catherine Pollard, Senior Director Strategic Operations UK, Clinical Development at Moderna

19:00 – 20:00 – Networking, drinks & nibbles

   Register Now